Vivien Bramwell - Concepedia

Author

Vivien Bramwell

Also Known As

Bernard, Philip S., V Bramwell, V H Bramwell, VIVIEN H.C. BRAMWELL, Vivian H Bramwell, Vivien Bramwell, Vivien H Bramwell, Vivien H C Bramwell, Vivien H. Bramwell, Vivien H. C. Bramwell

130

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

Queen's University Ottawa Regional Cancer Foundation Western University University of Calgary Sunnybrook Health Science Centre

About

Vivien Bramwell is an author at Queen's University specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	3.3K
2	Health Sciences	5	5	730
3	Cell Biology	4	4	735
4	Public Health	1	1	308
5	Biostatistics	1	1	308

Vivien Bramwell

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 Charles D. Blanke, Cathryn Rankin, George D. Demetri, Journal of Clinical Oncology	2008	1.1K
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Michael C. Heinrich, Kouros Owzar, Christopher L. Corless, Journal of Clinical Oncology	2008	649
Soft tissue sarcomas of adults: state of the translational science. Ernest C. Borden, Laurence H. Baker, Robert S. Bell, PubMed Single Gene FamilyImatinib MesylateGastrointestinal OncologyMedicineTranslational Science	2003	616
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial Penella J. Woll, Peter Reichardt, Axel Le Cesne, The Lancet Oncology Surgical OncologySoft-tissue SarcomaMedicineEortc 62931Metronomic Therapy	2012	572
<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy Kathleen I. Pritchard, Lois E. Shepherd, Frances P. O’Malley, New England Journal of Medicine	2006	508
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup Robert L. Souhami, Alan Craft, Jan W. van der Eijken, The Lancet Surgical OncologyMedicineCancer ManagementMetronomic TherapyEuropean Osteosarcoma Intergroup	1997	381
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen Stephen Chia, Vivien Bramwell, Dongsheng Tu, Clinical Cancer Research Breast OncologyPathologyTotal RnaGene Expression ProfilingIhc Profiling	2012	308
Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases George N. Naumov, Jason L. Townson, Ian C. MacDonald, Breast Cancer Research and Treatment Breast OncologyMedicinePharmacologyLate-developing MetastasesPathology	2003	305
Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas Vivien Bramwell, Henning T. Mouridsen, Armando Santoro, European Journal of Cancer and Clinical Oncology Surgical OncologyCyclophosphamide Versus IfosfamideMedicineFinal ReportMetronomic Therapy	1987	242
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 Mark N. Levine, Kathleen I. Pritchard, Vivien Bramwell, Journal of Clinical Oncology	2005	218

Page 1